Showing: 2 Results
Trial
Neuroscience Institute

18-513: A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor XA Inhibitor

Active not recruiting

18-513:  The purpose of this study is to evaluate the effect of andexanet alfa (andexanet) versus usual care on the rate of effective homostasis.

Contact: Stephanie Kohlrus 217-545-3013
Trial
Simmons Cancer Institute

ASND0029 "IL Believe": A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in

Active recruiting

This study is investigating experimental drugs TransCon IL-2 β/γ and TransCon TLR7/8 for the treatment of a

Contact: Kathy Robinson 217-545-1946